Switch theme
Sign up to access all valuation multiples
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
1968
6.4K+
LTM Revenue $1.6B
LTM EBITDA $323M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Virbac has a last 12-month revenue (LTM) of $1.6B and a last 12-month EBITDA of $323M.
In the most recent fiscal year, Virbac achieved revenue of $1.6B and an EBITDA of $310M.
Virbac expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Virbac valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $323M | XXX | $310M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $256M | XXX | $256M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $174M | XXX | $163M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $134M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Virbac's stock price is EUR 324 (or $364).
Virbac has current market cap of EUR 2.7B (or $3.0B), and EV of EUR 2.9B (or $3.2B).
See Virbac trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $3.0B | XXX | XXX | XXX | XXX | $20.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Virbac has market cap of $3.0B and EV of $3.2B.
Virbac's trades at 2.1x EV/Revenue multiple, and 10.4x EV/EBITDA.
Equity research analysts estimate Virbac's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Virbac has a P/E ratio of 17.5x.
See valuation multiples for Virbac and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.0x | XXX | 10.4x | XXX | XXX | XXX |
| EV/EBIT | 12.6x | XXX | 12.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.5x | XXX | 18.7x | XXX | XXX | XXX |
| EV/FCF | 24.9x | XXX | 23.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVirbac's last 12 month revenue growth is 6%
Virbac's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Virbac's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Virbac's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Virbac and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Mad Paws | XXX | XXX | XXX | XXX | XXX | XXX |
| i-Tail | XXX | XXX | XXX | XXX | XXX | XXX |
| Central Garden & Pet | XXX | XXX | XXX | XXX | XXX | XXX |
| Dogness | XXX | XXX | XXX | XXX | XXX | XXX |
| Freshpet | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Virbac acquired XXX companies to date.
Last acquisition by Virbac was XXXXXXXX, XXXXX XXXXX XXXXXX . Virbac acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Virbac founded? | Virbac was founded in 1968. |
| Where is Virbac headquartered? | Virbac is headquartered in France. |
| How many employees does Virbac have? | As of today, Virbac has 6.4K+ employees. |
| Is Virbac publicy listed? | Yes, Virbac is a public company listed on PAR. |
| What is the stock symbol of Virbac? | Virbac trades under VIRP ticker. |
| When did Virbac go public? | Virbac went public in 1989. |
| Who are competitors of Virbac? | Similar companies to Virbac include e.g. Mad Paws, i-Tail, Central Garden & Pet, Dogness. |
| What is the current market cap of Virbac? | Virbac's current market cap is $3.0B |
| What is the current revenue of Virbac? | Virbac's last 12 months revenue is $1.6B. |
| What is the current revenue growth of Virbac? | Virbac revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Virbac? | Current revenue multiple of Virbac is 2.0x. |
| Is Virbac profitable? | Yes, Virbac is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Virbac? | Virbac's last 12 months EBITDA is $323M. |
| What is Virbac's EBITDA margin? | Virbac's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Virbac? | Current EBITDA multiple of Virbac is 10.0x. |
| What is the current FCF of Virbac? | Virbac's last 12 months FCF is $130M. |
| What is Virbac's FCF margin? | Virbac's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Virbac? | Current FCF multiple of Virbac is 24.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
